Cencora, Inc. (NYSE:COR) Shares Bought by Allworth Financial LP

Allworth Financial LP grew its stake in shares of Cencora, Inc. (NYSE:COR) by 22.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,672 shares of the company’s stock after acquiring an additional 310 shares during the period. Allworth Financial LP’s holdings in Cencora were worth $376,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of COR. New Millennium Group LLC acquired a new position in shares of Cencora during the 2nd quarter worth approximately $26,000. TCTC Holdings LLC acquired a new position in shares of Cencora during the 1st quarter worth approximately $29,000. TFO Wealth Partners LLC acquired a new position in shares of Cencora during the 1st quarter worth approximately $30,000. MFA Wealth Advisors LLC acquired a new position in shares of Cencora during the 2nd quarter worth approximately $30,000. Finally, LRI Investments LLC acquired a new position in shares of Cencora during the 1st quarter worth approximately $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at $2,656,970.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,461,153 shares of company stock worth $1,073,075,720. Insiders own 15.80% of the company’s stock.

Analyst Ratings Changes

COR has been the subject of several research reports. Evercore ISI cut their price objective on Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Leerink Partners lowered their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Robert W. Baird decreased their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research report on Friday, September 6th. Bank of America reiterated a “neutral” rating and issued a $245.00 price objective (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. upped their target price on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $259.44.

Cencora Price Performance

NYSE COR opened at $231.79 on Wednesday. Cencora, Inc. has a 52 week low of $182.75 and a 52 week high of $247.66. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The stock has a market cap of $46.23 billion, a price-to-earnings ratio of 25.36, a price-to-earnings-growth ratio of 1.40 and a beta of 0.44. The company has a 50-day moving average price of $232.04 and a two-hundred day moving average price of $230.75.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The firm had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. During the same quarter in the prior year, the firm earned $2.92 EPS. Cencora’s quarterly revenue was up 10.8% on a year-over-year basis. Analysts forecast that Cencora, Inc. will post 13.63 EPS for the current year.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.